35975-69-0

Usage

Uses

Used in Research and Diagnostics:
NSC199383 is used as a biomarker for oxidative stress and DNA damage in various research and diagnostic applications. Its presence in cells indicates the level of oxidative stress and potential DNA damage, which is crucial for understanding the mechanisms underlying various diseases and conditions.
Used in Cancer Research:
In the field of cancer research, NSC199383 is utilized to study its potential role in cancer development and progression. Its association with oxidative stress and DNA damage makes it a valuable tool for investigating the molecular pathways and processes that contribute to tumorigenesis and cancer progression.
Used in Aging and Neurodegenerative Disease Research:
NSC199383 is employed as a biomarker in research related to aging and neurodegenerative diseases. Oxidative stress is a common factor in the pathogenesis of these conditions, and the measurement of NSC199383 can provide insights into the extent of oxidative damage and its impact on cellular function and health.
Used in Cardiovascular Disease Research:
In cardiovascular disease research, NSC199383 is used to assess the role of oxidative stress in the development and progression of heart diseases. By measuring the levels of this biomarker, researchers can better understand the contribution of oxidative stress to cardiovascular pathophysiology and identify potential therapeutic targets.
Used in Therapeutic Target Identification:
NSC199383 is also explored as a potential therapeutic target for the prevention and treatment of oxidative stress-related conditions. By modulating the pathways and processes associated with this biomarker, it may be possible to develop interventions that mitigate the effects of oxidative stress and protect against related health issues.

InChI:InChI=1/C11H9NO4/c1-16-8-4-2-3-6-9(8)12-5-7(10(6)13)11(14)15/h2-5H,1H3,(H,12,13)(H,14,15)

Upstream product

• 71082-34-3 ethyl 1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylate 
• 104007-09-2 2-[(2-methoxyphenylamino)-methylene]-malonic acid diethyl ester 
• 90-04-0 2-methoxy-phenylamine 

Downstream Products

• 1314230-69-7 1,4-dihydro-8-methoxy-4-oxo-1-pentyl-N-tricyclo[3.3.1.13,7]dec-1-yl-3-quinolinecarboxamide 

Relevant academic research and scientific papers

4-oxo-1,4-dihydroquinoline-3-carboxamide as selective ligand for cannabinoid receptor 2 for diagnosis and therapy

The present invention is directed to new compounds selectively binding the cannabinoid 2 receptor. In addition, the invention relates to the use of said compounds for determining cannabinoid receptor 2 (CB2)-selective receptor localization and density, preferably in the central nervous system (CNS), the peripheral nervous system (PNS), heart, liver, gastrointestinal tract, spleen, pancreas, kidney, testis, ovary and/or the prostate. Moreover, the invention pertains to the use of said compounds in the diagnosis, prophylaxis and/or therapy of CB2 receptor-related diseases.

Discovery of a fluorinated 4-oxo-quinoline derivative as a potential positron emission tomography radiotracer for imaging cannabinoid receptor type 2

The cannabinoid receptor type 2 (CB2) is part of the endocannabinoid system and has gained growing attention in recent years because of its important role in neuroinflammatory/neurodegenerative diseases. Recently, we reported on a carbon-11 labeled 4-oxo-

Investigations on the 4-quinolone-3-carboxylic acid motif. 4. Identification of new potent and selective ligands for the cannabinoid type 2 receptor with diverse substitution patterns and antihyperalgesic effects in mice

Experimental evidence suggests that selective CB2 receptor modulators may provide access to antihyperalgesic agents devoid of psychotropic effects. Taking advantage of previous findings on structure-activity/selectivity relationships for a class of 4-quin

Evaluation of 3-carboxy-4(1H)-quinolones as inhibitors of human protein kinase CK2

Due to the emerging role of protein kinase CK2 as a molecule that participates not only in the development of some cancers but also in viral infections and inflammatory failures, small organic inhibitors of CK2, besides application in scientific research, may have therapeutic significance. In this paper, we present a new class of CK2 inhibitors-3-carboxy-4(1H)-quinolones. This class of inhibitors has been selected via receptor-based virtual screening of the Otava compound library. It was revealed that the most active compounds, 5,6,8-trichloro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (7) (IC 50 = 0.3 μM) and 4-oxo-1,4-dihydrobenzo[h]quinoline-3-carboxylic acid (9) (IC50 = 1 μM), are ATP competitive (Ki values are 0.06 and 0.28 μM, respectively). Evaluation of the inhibitors on seven protein kinases shows considerable selectivity toward CK2. According to theoretical calculations and experimental data, a structural model describing the key features of 3-carboxy-4(1H)-quinolones responsible for tight binding to CK2 active site has been developed.